154 chapter 2 Table 24. Estimated pooled test performance of combined BRAF/RAS mutation analysis in Bethesda IV thyroid nodules ni Bethesda IV test + (BRAF+) test + (RAS+) test - test ? nH (%) TP FP FN TN malignant (TP+FN/ni) sensitivity (95% CI), % specificity (95% CI), % LR+ (95% CI) LR- (95% CI) Moses 2010 110 3 8 99 0 110 (100%) 7 4 22 77 26% 24 (10-44) 95 (88-99) 4.89 (1.54-15.48) 0.80 (0.65-0.99) Nikiforov 2011 214 2 34 178 0 214 (100%) 31 5 27 151 27% 53 (40-67) 97 (93-99) 16.68 (6.81-40.82) 0.48 (0.36-0.63) Ohori 2013 424 7 50 327 40 384 (100%) 53 4 61 266 27% 46 (37-56) 99 (96-100) 31.38 (11.63-84.66) 0.54 (0.46-0.64) BeaudenonHuibregtse 2014 38 0 5 33 0 19 (50%) 4 1 2 12 16% 67 (22-96) 92 (64-100) 8.67 (1.21-61.91) 0.36 (0.12-1.13) Danilovic 2014 20 4 0 16 0 20 (100%) 4 0 3 13 35% 57 (18-90) 100 (75-100) 15.75 (0.97-256.33) 0.45 (0.21-1.00) Nikiforov 2014 143 2 24 117 0 143 (100%) 21 5 18 99 27% 54 (37-70) 95 (89-98) 11.20 (4.54-27.64) 0.48 (0.34-0.68) Giovanella 2015 61 0 4 57 0 61 (100%) 3 1 13 44 26% 19 (4-46) 98 (88-100) 8.44 (0.94-75.40) 0.83 (0.65-1.06) Rossi 2015 37 4 2 31 0 17 (46%) 5 1 3 8 22% 62 (24-91) 89 (52-100) 5.62 (0.82-38.53) 0.42 (0.17-1.06) Valderrabano 2016 58 0 13 44 1 37 (65%) 8 3 8 18 28% 62 (24-91) 86 (64-97) 3.50 (1.10-11.13) 0.58 (0.35-0.98) POOLED RESULTS 1,105 22 140 902 41 1,005 (94.5%) 136 24 157 688 26.5% 46.0 (37.1-55.2) 96.4 (94.0-97.8) 12.70 (7.41-21.8) 0.56 (0.47-0.66) FN: false negative. FP: false positive. LR+: positive likelihood ratio. LR-: negative likelihood ratio. nH: number of indeterminate thyroid nodules with conclusive index test and histopathological follow-up. ni: number of indeterminate thyroid nodules. test+: number of positive index tests. test-: number of negative index tests. test?: number of unknown or nondiagnostic index tests. TN: true negative. TP: true positive.
RkJQdWJsaXNoZXIy MTk4NDMw